Skip to main content
Erschienen in: International Journal of Clinical Oncology 2/2017

15.10.2016 | Original Article

Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study

verfasst von: Naoto Kamiya, Hiroyoshi Suzuki, Takahito Suyama, Masayuki Kobayashi, Satoshi Fukasawa, Nobuyuki Sekita, Kazuo Mikami, Naoki Nihei, Yukio Naya, Tomohiko Ichikawa

Erschienen in: International Journal of Clinical Oncology | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

A retrospective, multi-institutional collaborative study was conducted to evaluate the impact of second transurethral resection (TUR) on the clinical outcome of non-muscle invasive high-grade bladder cancer and to identify predictors of invasion to the lamina propria (pT1) or deeper and residual tumor at the second TUR.

Methods

The clinical and pathological features of 198 patients with non-muscle invasive high-grade bladder cancer treated in five medical institutions from April 1990 to March 2013 were reviewed retrospectively. All patients underwent a second TUR within a mean of 1.5 months after the first resection. Clinicopathological findings of the first and second TURs were compared. Cancer-specific survival and recurrence-free survival were evaluated. Univariate and multivariate analyses for predictors of residual cancer at the second TUR were performed using a logistic regression model.

Results

At the second TUR, no tumor was found in 111 (56 %) patients, and 87 (44 %) had residual cancer. At the first TUR, five pT1 patients (3 %) were upstaged to pT2, one pTa patient (1 %) was upstaged to pT1, and 12 G2 patients (6 %) had their tumor upgraded to G3. Patients the group with less than stage pT1 cancer at the second TUR had significantly better survival than those in the group with stage pT1 or deeper cancer. Tumor multiplicity at the first resection was an independent risk factor for pT1 or deeper tumor at the second TUR.

Conclusion

A second TUR is a valuable diagnostic procedure for accurate staging of non-muscle invasive high-grade bladder cancer. Tumor multiplicity at the first TUR was a significant independent predictor of pT1 or deeper tumor at the second TUR.
Literatur
1.
Zurück zum Zitat Kakehi Y, Hirao Y, Kim WJ et al (2010) Bladder Cancer Working Group report. Jpn J Clin Oncol 40:57–64CrossRef Kakehi Y, Hirao Y, Kim WJ et al (2010) Bladder Cancer Working Group report. Jpn J Clin Oncol 40:57–64CrossRef
2.
Zurück zum Zitat Kitamura H, Kakehi Y (2015) Treatment and management of high-grade T1 bladder cancer: what should we do after second TUR? Jpn J Clin Oncol 45:315–322CrossRefPubMed Kitamura H, Kakehi Y (2015) Treatment and management of high-grade T1 bladder cancer: what should we do after second TUR? Jpn J Clin Oncol 45:315–322CrossRefPubMed
3.
Zurück zum Zitat Burger M, Catto JW, Dalbagni G et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63:234–241CrossRefPubMed Burger M, Catto JW, Dalbagni G et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63:234–241CrossRefPubMed
4.
Zurück zum Zitat Babjuk M, Burger M, Zigeuner R et al (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64:639–653CrossRefPubMed Babjuk M, Burger M, Zigeuner R et al (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64:639–653CrossRefPubMed
5.
Zurück zum Zitat Kirkali Z, Chan T, Manoharan M et al (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66:4–34CrossRefPubMed Kirkali Z, Chan T, Manoharan M et al (2005) Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 66:4–34CrossRefPubMed
6.
Zurück zum Zitat Herr HW (1999) The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162:74–76CrossRefPubMed Herr HW (1999) The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 162:74–76CrossRefPubMed
7.
Zurück zum Zitat Schips L, Augustin H, Zigeuner RE et al (2002) Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 59:220–223CrossRefPubMed Schips L, Augustin H, Zigeuner RE et al (2002) Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 59:220–223CrossRefPubMed
8.
Zurück zum Zitat Divrik RT, Sahin AF, Yildirim U et al (2010) Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomized clinical trial. Eur Urol 58:185–190CrossRefPubMed Divrik RT, Sahin AF, Yildirim U et al (2010) Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomized clinical trial. Eur Urol 58:185–190CrossRefPubMed
9.
Zurück zum Zitat Vianello A, Costantini E, Del Zingaro M et al (2011) Repeated white light transurethral resection of the bladder in nonmuscle-invasive urothelial bladder cancers: systematic review and meta-analysis. J Endourol 25:1703–1712CrossRefPubMed Vianello A, Costantini E, Del Zingaro M et al (2011) Repeated white light transurethral resection of the bladder in nonmuscle-invasive urothelial bladder cancers: systematic review and meta-analysis. J Endourol 25:1703–1712CrossRefPubMed
12.
Zurück zum Zitat Hall MC, Chang SS, Dalbagni G et al (2007) Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178:2314–2330CrossRefPubMed Hall MC, Chang SS, Dalbagni G et al (2007) Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178:2314–2330CrossRefPubMed
13.
Zurück zum Zitat Nieder AM, Brausi M, Lamm D et al (2005) Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 66:108–125CrossRefPubMed Nieder AM, Brausi M, Lamm D et al (2005) Management of stage T1 tumors of the bladder: International Consensus Panel. Urology 66:108–125CrossRefPubMed
14.
Zurück zum Zitat Cookson MS, Herr HW, Zhang ZF et al (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158:62–67CrossRefPubMed Cookson MS, Herr HW, Zhang ZF et al (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158:62–67CrossRefPubMed
15.
Zurück zum Zitat Kulkarni GS, Hakenberg OW, Gschwend JE et al (2010) An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 57:60–70CrossRefPubMed Kulkarni GS, Hakenberg OW, Gschwend JE et al (2010) An updated critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previously T1G3) bladder cancer. Eur Urol 57:60–70CrossRefPubMed
16.
Zurück zum Zitat van Rhijn BW, Burger M, Lotan Y et al (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56:430–442CrossRefPubMed van Rhijn BW, Burger M, Lotan Y et al (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56:430–442CrossRefPubMed
17.
Zurück zum Zitat Bertz S, Denzinger S, Otto W et al (2011) Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series. Histopathology 59:722–732CrossRefPubMed Bertz S, Denzinger S, Otto W et al (2011) Substaging by estimating the size of invasive tumour can improve risk stratification in pT1 urothelial bladder cancer-evaluation of a large hospital-based single-centre series. Histopathology 59:722–732CrossRefPubMed
18.
Zurück zum Zitat Roupret M, Seisen T, Comperat E et al (2013) Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review. J Urol 189:2069–2076CrossRefPubMed Roupret M, Seisen T, Comperat E et al (2013) Prognostic interest in discriminating muscularis mucosa invasion (T1a vs T1b) in nonmuscle invasive bladder carcinoma: French national multicenter study with central pathology review. J Urol 189:2069–2076CrossRefPubMed
19.
Zurück zum Zitat Andius P, Johansson SL, Holmang S (2007) Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 70:758–762CrossRefPubMed Andius P, Johansson SL, Holmang S (2007) Prognostic factors in stage T1 bladder cancer: tumor pattern (solid or papillary) and vascular invasion more important than depth of invasion. Urology 70:758–762CrossRefPubMed
20.
Zurück zum Zitat Lamm D, Persad R, Brausi M et al (2014) Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. J Urol 191:20–27CrossRefPubMed Lamm D, Persad R, Brausi M et al (2014) Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition. J Urol 191:20–27CrossRefPubMed
21.
Zurück zum Zitat Pasin E, Josephson DY, Mitra AP et al (2008) Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 10:31–43PubMedPubMedCentral Pasin E, Josephson DY, Mitra AP et al (2008) Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev Urol 10:31–43PubMedPubMedCentral
22.
Zurück zum Zitat van Rhijn BW, van der Kwast TH, Alkhateeb SS et al (2012) A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 61:378–384CrossRefPubMed van Rhijn BW, van der Kwast TH, Alkhateeb SS et al (2012) A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol 61:378–384CrossRefPubMed
23.
Zurück zum Zitat Kunieda F, Kitamura H, Niwakawa M et al (2012) Watchful waiting versus intravesical BCG therapy for high-grade pT1 bladder cancer with pT0 histology after second transurethral resection: Japan Clinical Oncology Group Study JCOG1019. Jpn J Clin Oncol 42:1094–1098CrossRefPubMed Kunieda F, Kitamura H, Niwakawa M et al (2012) Watchful waiting versus intravesical BCG therapy for high-grade pT1 bladder cancer with pT0 histology after second transurethral resection: Japan Clinical Oncology Group Study JCOG1019. Jpn J Clin Oncol 42:1094–1098CrossRefPubMed
24.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC et al (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York Edge SB, Byrd DR, Compton CC et al (eds) (2010) AJCC cancer staging manual, 7th edn. Springer, New York
25.
Zurück zum Zitat Mostofi FK, Sobin LH, Torloni H (1973). Histological typing of urinary bladder tumors. World Health Organization, Geneva 1973 Mostofi FK, Sobin LH, Torloni H (1973). Histological typing of urinary bladder tumors. World Health Organization, Geneva 1973
26.
Zurück zum Zitat Grimm M-O, Steinhoff CH, Simon X et al (2003) Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 170:433–437CrossRefPubMed Grimm M-O, Steinhoff CH, Simon X et al (2003) Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 170:433–437CrossRefPubMed
27.
Zurück zum Zitat Lazica DA, Roth S, Brandt AS et al (2014) Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center. Urol Int 92:131–135CrossRefPubMed Lazica DA, Roth S, Brandt AS et al (2014) Second transurethral resection after Ta high-grade bladder tumor: a 4.5-year period at a single university center. Urol Int 92:131–135CrossRefPubMed
28.
Zurück zum Zitat Herr HW, Donat SM (2008) Quality control in transurethral resection of bladder tumours. BJU Int 102:1242–1246CrossRefPubMed Herr HW, Donat SM (2008) Quality control in transurethral resection of bladder tumours. BJU Int 102:1242–1246CrossRefPubMed
29.
Zurück zum Zitat Shindo T, Masumori N, Kitamura H et al (2014) Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer: multicenter retrospective study by the Sapporo Medical University Urologic Oncology Consortium (SUOC). World J Urol 32:1281–1285CrossRefPubMed Shindo T, Masumori N, Kitamura H et al (2014) Clinical significance of definite muscle layer in TUR specimen for evaluating progression rate in T1G3 bladder cancer: multicenter retrospective study by the Sapporo Medical University Urologic Oncology Consortium (SUOC). World J Urol 32:1281–1285CrossRefPubMed
30.
Zurück zum Zitat Takaoka E, Matsui Y, Inoue T et al (2013) Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era. Jpn J Clin Oncol 43:404–409CrossRefPubMed Takaoka E, Matsui Y, Inoue T et al (2013) Risk factors for intravesical recurrence in patients with high-grade T1 bladder cancer in the second TUR era. Jpn J Clin Oncol 43:404–409CrossRefPubMed
31.
Zurück zum Zitat Segal R, Yafi FA, Brimo F et al (2012) Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int 109:1026–1030CrossRefPubMed Segal R, Yafi FA, Brimo F et al (2012) Prognostic factors and outcome in patients with T1 high-grade bladder cancer: can we identify patients for early cystectomy? BJU Int 109:1026–1030CrossRefPubMed
32.
Zurück zum Zitat Dalbagni G, Vora K, Kaag M et al (2009) Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 56:903–910CrossRefPubMed Dalbagni G, Vora K, Kaag M et al (2009) Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 56:903–910CrossRefPubMed
Metadaten
Titel
Clinical outcomes of second transurethral resection in non-muscle invasive high-grade bladder cancer: a retrospective, multi-institutional, collaborative study
verfasst von
Naoto Kamiya
Hiroyoshi Suzuki
Takahito Suyama
Masayuki Kobayashi
Satoshi Fukasawa
Nobuyuki Sekita
Kazuo Mikami
Naoki Nihei
Yukio Naya
Tomohiko Ichikawa
Publikationsdatum
15.10.2016
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 2/2017
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-1048-z

Weitere Artikel der Ausgabe 2/2017

International Journal of Clinical Oncology 2/2017 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.